Leerink Partnrs Research Analysts Raise Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Investment analysts at Leerink Partnrs increased their Q3 2024 earnings per share estimates for United Therapeutics in a report issued on Tuesday, March 26th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will earn $6.90 per share for the quarter, up from their previous estimate of $6.31. Leerink Partnrs currently has a "Outperform" rating on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q4 2024 earnings at $6.94 EPS, FY2025 earnings at $27.09 EPS, FY2026 earnings at $27.29 EPS and FY2027 earnings at $26.52 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to analysts' expectations of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. United Therapeutics's revenue was up 25.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.67 earnings per share.

A number of other brokerages have also weighed in on UTHR. SVB Leerink initiated coverage on shares of United Therapeutics in a research report on Monday, February 5th. They issued an "outperform" rating and a $330.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. The Goldman Sachs Group raised shares of United Therapeutics from a "sell" rating to a "neutral" rating and boosted their target price for the stock from $213.00 to $215.00 in a report on Monday, February 12th. Wells Fargo & Company increased their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. Finally, Wedbush reaffirmed an "outperform" rating and set a $308.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $294.40.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded down $13.55 during trading on Friday, reaching $229.72. 1,114,801 shares of the company's stock were exchanged, compared to its average volume of 532,211. The firm's 50-day moving average price is $226.00 and its 200 day moving average price is $227.44. The company has a market cap of $10.81 billion, a P/E ratio of 11.58 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.28 and a current ratio of 4.41. United Therapeutics has a 1-year low of $204.44 and a 1-year high of $261.54.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 6,000 shares of the company's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the transaction, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $215.01, for a total value of $1,290,060.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares of the company's stock, valued at $7,869,150.99. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Christopher Patusky sold 1,680 shares of the business's stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $224.00, for a total value of $376,320.00. Following the completion of the transaction, the director now directly owns 4 shares in the company, valued at approximately $896. The disclosure for this sale can be found here. Insiders have sold a total of 91,130 shares of company stock valued at $21,299,958 over the last ninety days. 12.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its stake in shares of United Therapeutics by 73.7% in the first quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company's stock worth $300,585,000 after purchasing an additional 710,668 shares during the last quarter. Norges Bank purchased a new position in United Therapeutics in the 4th quarter worth approximately $100,519,000. BlackRock Inc. boosted its stake in United Therapeutics by 7.3% during the 2nd quarter. BlackRock Inc. now owns 5,096,685 shares of the biotechnology company's stock valued at $1,125,093,000 after purchasing an additional 344,724 shares during the last quarter. State Street Corp raised its stake in shares of United Therapeutics by 15.9% in the first quarter. State Street Corp now owns 1,795,102 shares of the biotechnology company's stock worth $402,031,000 after purchasing an additional 245,747 shares during the last quarter. Finally, Avidity Partners Management LP purchased a new position in United Therapeutics in the 4th quarter worth about $52,158,000. Institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.